Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments

Article Rheumatology

Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis

Elisabeth Simader et al.

Summary: Patients with inflammatory joint diseases under DMARD therapy show reduced humoral responses to the first dose of mRNA vaccines, but achieve excellent final responses after completing the full course of two immunizations.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Laura Boekel et al.

Summary: This study found that older patients with autoimmune diseases on specific immunosuppressive drugs may have delayed antibody development after the first COVID-19 vaccination. However, second or repeated exposure to SARS-CoV-2, either through infection or vaccination, can improve humoral immunity in these patients. Delaying the second dose of COVID-19 vaccines in patients receiving immunosuppressive drugs should be avoided, and future studies including younger patients are needed to confirm the generalizability of the results.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Yolanda Braun-Moscovici et al.

Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Daniel Mrak et al.

Summary: The study found that RTX-treated patients can develop SARS-CoV-2-specific antibodies after vaccination, but only if peripheral B cells at least partially repopulate. Additionally, more than half of the vaccinated patients developed SARS-CoV-2-specific T cells, which may provide protective effects regardless of humoral immune responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3

Jeffrey R. Curtis et al.

Summary: A task force composed of rheumatologists, infectious disease specialists, and public health physicians developed 74 draft guidance statements regarding the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases, aiming to provide direction to rheumatology providers and facilitate vaccination strategies for RMD patients based on limited clinical data.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Review Rheumatology